Anna Morra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Morra has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Anna Jakubowska
Department of Genetics and Pathology, International Hereditary Cancer Center Pomeranian Medical University Szczecin Poland
2 shared publicationsAnna Marie Mulligan
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
2 shared publicationsAnthony Howell
Division of Cancer Sciences University of Manchester Manchester UK
2 shared publicationsArto Mannermaa
Translational Cancer Research Area University of Eastern Finland Kuopio Finland
2 shared publicationsCamilla Wendt
Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet Stockholm Sweden
2 shared publicationsDimitrios Mavroudis
Department of Medical Oncology University Hospital of Heraklion Heraklion Greece
2 shared publications
Latest Publications
- Open Access
- 3 July 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 16142-16162
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
Background: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers.Aim: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS.Methods: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death.Results: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)].Conclusion: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
- 3 July 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 16142-16162
Open AccessAssociation of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
Background: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers.Aim: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS.Methods: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death.Results: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)].Conclusion: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
- Open Access
- 23 February 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (3) , 475-486
The impact of coding germline variants on contralateral breast cancer risk and survival
- 23 February 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (3) , 475-486
Open AccessThe impact of coding germline variants on contralateral breast cancer risk and survival